Ayala Pharmaceuticals EV/EBITDA
Qual é o EV/EBITDA de Ayala Pharmaceuticals?
O EV/EBITDA de Ayala Pharmaceuticals Inc. é 2.04
Qual é a definição de EV/EBITDA?
EV/EBITDA é o valor da empresa dividido pelo lucro antes de juros, impostos, depreciação e amortização. É uma medida de quão cara é uma ação e é mais frequentemente válida para comparações entre empresas do que da relação entre preço e lucro. Ele mede o preço (na forma de valor da empresa) que um investidor paga em benefício do fluxo de caixa da empresa (na forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de empresas na Setor Health Care em NASDAQ em comparação com Ayala Pharmaceuticals
O que Ayala Pharmaceuticals faz?
advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Empresas com ev/ebitda semelhantes a Ayala Pharmaceuticals
- Eastern Platinum tem EV/EBITDA de 2.02
- Evadix Sa tem EV/EBITDA de 2.03
- Modern Living Investments tem EV/EBITDA de 2.03
- NOVATEK JSC tem EV/EBITDA de 2.03
- Epsilon tem EV/EBITDA de 2.03
- The Indian Card Clothing tem EV/EBITDA de 2.03
- Ayala Pharmaceuticals tem EV/EBITDA de 2.04
- Societe Francaise de Gestion et d'Investissement tem EV/EBITDA de 2.04
- TXCOM Societe Anonyme tem EV/EBITDA de 2.04
- ECI Technology tem EV/EBITDA de 2.04
- Eurobio Scientific Societe anonyme tem EV/EBITDA de 2.04
- Dsv A/S tem EV/EBITDA de 2.05
- Altamir SCA tem EV/EBITDA de 2.06